Formulation and evaluation of inclusion complex Tablet of Furazolidone

Abstract

Furazolidone is a nitro furan antimicrobial agent used in the treatment of
diarrhea or enteritis caused by bacteria or protozoan infections. Furazolidone is
also active in treating typhoid fever, cholera and salmonella infections. In
present research work an attempt has been made to prepare inclusion complex
tablets of Furazolidone with increased rate of dissolution may leads to increase
bioavailability. Formulation of inclusion complex tablet of poorly soluble
Furazolidone by β Cyclodextrin and Hydroxypropyl β cyclodextrin by different
ratio (1:1), (1:2), (1:3) using kneading method. The papered inclusion complex
evaluated by phase solubility study optimized inclusion complex Furazolidone:
Hydroxypropyl β Cyclodextrin (1:2) ratio give enhanced solubility. After
optimization of inclusion complex of Furazolidone: Hydroxypropyl β
Cyclodextrin inclusion complex were prepared by direct compression method.
Sodium starches Glycolate, croscarmellose sodium, crospovidone are used as a
superdisintegrants.
Drug polymer interactions were investigated using Fourier transform infrared spectroscopy. The prepared
formulation were evaluated for various parameters like weight variation, hardness, friability, drug content,
disintegration time, wetting time, in vitro drug release, Batch D5was optimized formulation containing 5%
Crospovidone showed less disintegration time 20 sec and more than 99.54% drug release at 30 mint. Stability
studies were carried out at 40 ± 2°C /75 ± 5% RH for formulation D5 for 1 month Stability studies on the best
formulation indicated that there was no significant change found in hardness, disintegration time, wetting time and
drug release of tablets.